

Clinical Trial Protocol

Iranian Registry of Clinical Trials

13 Jun 2026

A Phase III, randomized, two armed, parallel, double blind, active controlled, equivalency clinical trial to determine the therapeutic efficacy and safety between Cetuximab (produced by CinnaGen) and FOLFIRI compared with Erbitux® (Cetuximab, the reference drug, produced by Merck Company) and FOLFIRI as first-line treatment for RAS wild-type Metastatic Colorectal Cancer

Protocol summary

Study aim

The aim of this study is to determine the equivalency of efficacy and safety of cetuximab (CinnaGen) versus Erbitux® (Merck) in progression free survival (PFS) when added to FOLFIRI (irinotecan plus leucovorin/ 5-fluorouracil continuous infusion) in patients with metastatic colorectal cancer (mCRC) without mutations in RAS genes

Design

A phase III, Active-controlled, Parallel, double-blind, randomized clinical trial

Settings and conduct

This is a multicenter, double-blinded study.

Participants/Inclusion and exclusion criteria

Inclusion: • Age of 18 years or older • Histologically confirmed adenocarcinoma of the colon or rectum • Having one or more bi-dimensionally measurable lesions as defined by RECIST Criteria • Adequate organ and marrow function Exclusion: • Previous exposure to an anti-EGFR therapy or irinotecan-based chemotherapy • Adjuvant treatment that was terminated 6 months or less before the start of treatment in our trial • The use of radiotherapy, surgery (excluding previous diagnostic biopsy), or any investigational drug in the 30-day period before the start of treatment in our trial • Female patients who are pregnant or lactating chemically or biologically similar to Cetuximab, irinotecan, 5-FU or leucovorin. • Patients with a history of another primary malignancy in less than 5 years, • Inability to comply with study and/or follow-up procedures

Intervention groups

Cetuximab 400 mg/m² for the first and 250 mg/m² for subsequent doses

Main outcome variables

Primary Endpoint: Progression Free Survival Secondary Endpoints: Overall Survival, Time to Treatment Failure, Objective Response Rate, Safety, and Immunogenicity.

General information

Reason for update

updating and changing of the Colorectal metastatic cancer treatment guideline

Acronym

IRCT registration information

IRCT registration number: **IRCT2017110821315N10**
Registration date: **2017-11-15, 1396/08/24**
Registration timing: **prospective**

Last update: **2024-02-20, 1402/12/01**

Update count: **3**

Registration date

2017-11-15, 1396/08/24

Registrant information

Name

Nassim Anjidani

Name of organization / entity

Orchid Pharmed

Country

Iran (Islamic Republic of)

Phone

+98 21 4347 3000

Email address

amini@orchidpharmed.com

Recruitment status

Recruitment complete

Funding source

CinnaGen Company

Expected recruitment start date

2017-11-30, 1396/09/09

Expected recruitment end date

2025-03-19, 1403/12/29

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

A Phase III, randomized, two armed, parallel, double blind, active controlled, equivalency clinical trial to determine the therapeutic efficacy and safety between Cetuximab (produced by CinnaGen) and FOLFIRI compared with Erbitux® (Cetuximab, the reference drug, produced by Merck Company) and FOLFIRI as first-line treatment for RAS wild-type Metastatic Colorectal Cancer

Public title

An equivalency clinical trial to determine the efficacy and safety between Cetuximab (produced by CinnaGen) compared with Erbitux® in RAS wild-type Metastatic Colorectal Cancer

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

male or female Age of 18 till 75 histologically confirmed adenocarcinoma of the colon or rectum having one or more bi-dimensionally measurable lesions as defined by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria metastatic disease that could not be resected for curative purposes immunohistochemical evidence of tumor EGFR expression (expanded wild-type RAS) Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less life expectancy of longer than 3 months (by clinical assessment) adequate organ and marrow function.

Exclusion criteria:

Previous exposure to an anti-EGFR therapy or irinotecan-based chemotherapy the use of radiotherapy, surgery (excluding previous diagnostic biopsy), or any investigational drug in the 30-day period before the start of treatment in our trial female patients who are pregnant or lactating patients with a history of another primary malignancy in less than 5 years, with the exception of non-melanoma skin cancer and carcinoma in-situ of uterine cervix patients with history of allergic reactions attributed to compounds chemically or biologically similar to Cetuximab, irinotecan, 5-FU or leucovorin adjuvant treatment that was terminated 6 months or less before the start of treatment in our trial inability to comply with study and/or follow-up procedures Subjects with known infection with HIV, HBV, HCV first line treatment in patient with right sided primary tumor

Age

From **18 years** old to **75 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Care provider
- Investigator

Sample size

Target sample size: **234**

Randomization (investigator's opinion)

Randomized

Randomization description

Eligible patients will be assigned to treatment with the use of a dynamic randomization algorithm that will be designed to achieve overall balance between groups; randomization will be stratified according to site of primary tumor and number of metastasis (1 or more than 1) with 1:2 allocation ratio. After randomization procedure, a code will be allocated to each patient that will be used as patient identifier throughout the study. The assigned code will be denoted by 4 initials (corresponding to the 2 first letter of the first name, the 2 first letter of the first surname) and 3 numbers (center code). Moreover, the code described is followed by study unique identification consisting of first three letters of the generic name (which is CET-) and 3 numbers (corresponding to the randomization number), e.g. ABCD001CET-001. The randomization number will be assigned in a consecutive way. concealment process: Randomization will not be exposed to those conducting the study and will be provided in sealed opaque envelopes with successive numbers. The original paper of randomized remains in the CRO Trial and after checking eligibility criteria, the randomization code is given to the prescriber by telephone. Randomization will not be exposed to the trial executers and will be provided to the researcher of each center in non-transparent sealed envelopes.

Blinding (investigator's opinion)

Double blinded

Blinding description

Both cetuximab products are indistinguishable for patients and health care providers. Since the route of administration is infusion, and the size and shape of the vial, cap, seal, aluminum and the color are quite similar, it is not possible to distinguish the type of brand from the appearance of vials and it will be possible to make patients blind about the treatment group which they have been allocated to

Placebo

Not used

Assignment

Parallel

Other design features**Secondary Ids**

1

Registry name

ClinicalTrial.gov

Secondary trial Id

NCT03391934

Registration date

2017-12-31, 1396/10/10

Ethics committees

1

Ethics committee

Name of ethics committee

Shahid Beheshti University of Medical Science

Street address

Tabnak St., Velenjak, Chamran High Way, Tehran

City

Tehran

Province

Tehran

Postal code

134423235

Approval date

2017-11-05, 1396/08/14

Ethics committee reference number

IR.SBMU.REC.1396.228

2

Ethics committee

Name of ethics committee

Tabriz University of Medical science

Street address

Tabriz University of Medical science, Tabriz

City

Tabriz

Province

East Azarbaijan

Postal code

41544

Approval date

2017-10-15, 1396/07/23

Ethics committee reference number

IR.TABRIZ.REC.1396.603

Health conditions studied

1

Description of health condition studied

RAS wild-type Metastatic Colorectal Cancer

ICD-10 code

C18.9, C20

ICD-10 code description

Malignant neoplasm of colon, Malignant neoplasm of rectum

Primary outcomes

1

Description

Assessment of Progression-Free Survival (PFS) time of Cetuximab and Erbitux®

Timepoint

a 12-month period

Method of measurement

PFS is defined as the time from the date of randomization to the first date of documentation progression (per investigator assessment) or death as a result of any cause.

Secondary outcomes

1

Description

Overall survival

Timepoint

a 12-month period

Method of measurement

the time from date of randomization to date of death due to any cause

2

Description

Objective response rate

Timepoint

a 12-month period

Method of measurement

RECIST criteria (Response Evaluation Criteria in Solid Tumors)

3

Description

Time to treatment failure

Timepoint

a 12-month period

Method of measurement

- Time of treatment failures define as the time from the date of randomization to the date of each of the following, - The treatment modalities did not destroy or modify the cancer cell. - The tumor either became larger (disease progression) or stayed the same size after treatment, - Death from any cause - Discontinuation of treatment

4

Description

Safety and frequency of AEs

Timepoint

a 12-month period

Method of measurement

Safety wills assess on the basis of reports of adverse events, laboratory-test results, and vital sign measurements

5

Description

Immunogenicity

Timepoint

Weeks 1, 2, 4, 10, 16, 22, 28, 34, 40 and 46

Method of measurement

assessment (antidrug antibody [ADA] and neutralizing antibody [nAb])

Intervention groups

1

Description

CinnaGen Cetuximab (produced by CinnaGen) 400 mg/m² for the first infusion, then weekly intravenous infusions of 250 mg/m², every week for 6 months

Category

Treatment - Drugs

2

Description

Erbix® 400 mg/m² for the first infusion, then weekly intravenous infusions of 250 mg/m², every week for 6 months

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Taleghani Hospital

Full name of responsible person

Dr.Sina Salari, Dr.Mojtaba Ghadyani

Street address

Tabnak St., Velenjak, Chamran High Way, Tehran, Iran

City

Tehran

Province

Tehran

Postal code

212365

Phone

+98 21 2293 7031

Email

hampegrad@gmail.com

2

Recruitment center

Name of recruitment center

Sheikh mofid clinic

Full name of responsible person

Dr. Hajiqolami, Dr. Sadeghi, Dr. Nekuee, Dr. Mehrzad, Dr. Sharifi

Street address

Sheikh mofid St., Feiz St., Isfahan

City

Isfahan

Province

Isfahan

Postal code

987456

Phone

+98 31 2368 0005

Email

valimehrzad@yahoo.com

3

Recruitment center

Name of recruitment center

Firozgar Hospital

Full name of responsible person

Dr. Mohsen Razavi

Street address

Behafarin St., Karimkhan Street, Valiasr Sq., Tehran

City

Tehran

Province

Tehran

Postal code

654125

Phone

+98 21 8893 7902

Email

s_m_raz@yahoo.com

4

Recruitment center

Name of recruitment center

Dr. Mortazavizadeh Clinic

Full name of responsible person

Dr. Mohammad Reza Mortazavi Zade

Street address

No. 25, Shahid haj Mohammadi Alley, Taleqani Blvd., Yazd, Iran

City

Yazd

Province

Yazd

Postal code

956214

Phone

+98 35 3725 0044

Email

mortazavizadeh@yahoo.com

5

Recruitment center

Name of recruitment center

Emam khomeini Hospital

Full name of responsible person

Dr. Farhad Shahi

Street address

End of Keshavarz Blvd., Tehran, Iran

City

Tehran

Province
Tehran
Postal code
5198622
Phone
+98 21 6658 1593
Email
F.shahi@yahoo.com

6

Recruitment center
Name of recruitment center
Bahonar hospital
Full name of responsible person
Dr. Vahid Moazed, DR. Behjat Kalantari
Street address
Shahid Gharani street, Kerman, Iran
City
Kerman
Province
Kerman
Postal code
2584136
Phone
+98 34 3223 5011
Fax
Email
Moazed_vahid@yahoo.com

7

Recruitment center
Name of recruitment center
Emam Reza Hospital
Full name of responsible person
Dr. AllahYari
Street address
Seyed Jamal Odin Asadabadi Street, Bojnurd, North Khorasan
City
bojnurd
Province
North Khorasan
Postal code
5214658
Phone
+98 58 4222 8111
Email
hadi81938@gmail.com

8

Recruitment center
Name of recruitment center
Shahid Ghazi hospital
Full name of responsible person
Dr Nejati, Dr Esfahani, Dr Chavoshi, Dr Raeisi
Street address
Golgasht St, Daneshgah St, Tabriz
City
Tabriz
Province

East Azarbaijan
Postal code
885544
Phone
+98 41 3334 3626
Email
ali_sfhn@yahoo.com

9

Recruitment center
Name of recruitment center
Amir hospital
Full name of responsible person
Dr. Alireza Rezvani
Street address
Rajaei Blvd, Shiraz, Fars
City
Shiraz
Province
Fars
Postal code
45974165
Phone
+98 71 3632 3731
Email
Dr.rezvani@hotmail.com

10

Recruitment center
Name of recruitment center
Masih Daneshvari hospital
Full name of responsible person
Dr. Adnan Khosravi
Street address
Darabad , Tehran
City
Tehran
Province
Tehran
Postal code
552266
Phone
+98 21 2712 2160
Email
adkhosravi@yahoo.com

11

Recruitment center
Name of recruitment center
Rahimi Hospital
Full name of responsible person
Dr. Mojtaba Gorji
Street address
Azadi Sq., Khoram Abad
City
Khoram Abad
Province
Lorestan
Postal code
7893214567

Phone

+98 21 3333 6143

Email

mogorji@yahoo.com

12**Recruitment center****Name of recruitment center**

Rasoul Akram Hospital

Full name of responsible person

Dr. Hossein Mirpour

Street address

Gil Sq, Gilan

City

Rasht

Province

Guilan

Postal code

1234569874

Phone

+98 13 3366 2217

Email

mirboloukmahdi@yahoo.com

13**Recruitment center****Name of recruitment center**

Rasoul e Akram Hospital

Full name of responsible person

Dr. Nafiseh Ansari Nezhad, Dr. Farshid Fardad, Dr. Nstaran Khoda Karim

Street address

Mansouri St., Niaiesh St., Sattar Khan, Tehran

City

Tehran

Province

Tehran

Postal code

4563217893

Phone

+98 21 6651 5001

Email

drfardad@yahoo.com

14**Recruitment center****Name of recruitment center**

Ghaem Hospital

Full name of responsible person

Dr. Alireza Bari, Dr Azimi

Street address

Ahmad abad St., Shariati Sq, Mashhad

City

Mashhad

Province

Razavi Khorasan

Postal code

7897412365

Phone

+98 51 3840 0000

Email

dr.alireza.baari@gmail.com

15**Recruitment center****Name of recruitment center**

Baghi at Allah Hospital

Full name of responsible person

Dr. Mojtaba Ghadiani

Street address

Mollasadra Street, Vanak Sq.

City

Tehran

Province

Tehran

Postal code

9638527418

Phone

+98 21 8805 0435

Email

ghadianymojtaba@yahoo.com

16**Recruitment center****Name of recruitment center**

Sina Hospital

Full name of responsible person

Dr. Mohsen Esfandbod

Street address

Emam Khomeini St, Tehran

City

Tehran

Province

Tehran

Postal code

12345432

Phone

+98 21 6634 8500

Email

sfandbod@sina.tums.ac.ir

17**Recruitment center****Name of recruitment center**

Saba Clinic

Full name of responsible person

Dr. Mohsen Khani

Street address

Amadgah St, Isfahan

City

Isfahan

Province

Isfahan

Postal code

9876789

Phone

+98 31 1220 9219

Email

khani.hot@gmail.com

18

Recruitment center

Name of recruitment center

Dr Razavi Clinic

Full name of responsible person

Dr Razavi

Street address

No. 482, Motahari St., Valiasr St., Tehran

City

Tehran

Province

Tehran

Postal code

1595813611

Phone

+98 21 8890 2645

Email

s_m_raz@yahoo.com

19

Recruitment center

Name of recruitment center

Seyed Alshohada Hospital

Full name of responsible person

Dr. Hajiqolami, Dr. Sadeghi, Dr. Nekuee, Dr. Mehrzad,
Dr. Sharifi

Street address

Saba Apartment, Kooie Mohammad Abad, Amadgah
St., Isfahan

City

Isfahan

Province

Isfahan

Postal code

۸۱۸۴۹۱۷۳۵۴

Phone

+98 31 2240 0219

Email

valimehrzad@yahoo.com

20

Recruitment center

Name of recruitment center

Baghaie 2 Hospital

Full name of responsible person

Dr Hoseinzade, Dr Ehsanpoor

Street address

Ahvaz, Golestan Highway, near Nabard Factory

City

Ahvaz

Province

Khuzestan

Postal code

۶۱۳۹۷۱۷۸۴۸

Phone

+98 61 3375 0000

Email

hoseinzadehmehran@gmail.com

21

Recruitment center

Name of recruitment center

Imam Ali Hospital

Full name of responsible person

Dr Mohammad doost

Street address

Daneshgahe payame noor St., Chamran St., Bojnoord

City

Bojnoord

Province

North Khorasan

Postal code

۹۴۱۷۶۹۴۷۳۵

Phone

+98 58 3229 7010

Email

hadi81938@gmail.com

22

Recruitment center

Name of recruitment center

Pardis Noor Niloo

Full name of responsible person

Dr Gorji

Street address

No. 30, Second Boostan, Pasdaran, Tehran

City

Tehran

Province

Tehran

Postal code

۱۶۶۴۸۵۵۷۱۱

Phone

+98 21 9100 8808

Email

mgorji@yahoo.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

CinnaGen company

Full name of responsible person

Mehran Montahabi Niyat

Street address

CinnaGen research and production Company. Simin
Dasht Industrial Park, Karaj, Alborz, Iran

City

Karaj

Province

Alborz

Postal code

3165933155

Phone

+98 26 3667 0334

Email

cinnagen@cinnagen.com

Grant name

Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
CinnaGen company
Proportion provided by this source
100
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Industry

Person responsible for general inquiries

Contact

Name of organization / entity
Orchid Pharmed company
Full name of responsible person
Dr. Hamidreza Kafi
Position
Medical Manager
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
No 42, Attar St., Vanak Sq, Tehran, Iran
City
Tehran
Province
Tehran
Postal code
1468813112
Phone
+98 21 4347 3000
Fax
Email
Kafi.H@orchidpharmed.com
Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity
Shahid Beheshti university of medical sciences
Full name of responsible person
Dr Hamid Rezvani
Position
Associated Professor
Latest degree
Subspecialist
Other areas of specialty/work
Hematology
Street address
AyatollahTaleghani Hospital, Shahid Erabi street.

Yaman street, Shahid Chamran highway
City
Tehran
Province
Tehran
Postal code
1468813112
Phone
+98 21 2293 7031
Fax
Email
hampegrad@gmail.com
Web page address

Person responsible for updating data

Contact

Name of organization / entity
Orchid Pharmed company
Full name of responsible person
Dr. Hamidreza Kafi
Position
مدیر واحد مديكال
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
No 42, Attar St., Vanak Sq, Tehran, Iran
City
Tehran
Province
Tehran
Postal code
1994766411
Phone
+98 21 4347 3000
Fax
Email
Kafi.H@orchidpharmed.com
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available